Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $7.68 Analyst target: $24.05 Upside: 213.15%
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California.
See the full interactive analysis & chart →Informational only — not investment advice.